Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CuRe: Placental Mesenchymal Stem Cells for Fetal Myelomeningocele
NCT04652908Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Jun 2021
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in myelomeningocele (MMC) (2 arms), sponsored by University of California, Davis. Primary endpoint: Safety of the PMSC-ECM Product. Started Jun 2021; status: recruiting.
02
Conditions
myelomeningocele (MMC)
Beyond the preview
Go deeper on NCT04652908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652908.